|
First-in-human study of ABBV-400, a novel c-Met–targeting antibody-drug conjugate, in advanced solid tumors: Results in colorectal cancer. |
| |
|
Stock and Other Ownership Interests - Abbott Laboratories; Abbvie; Amgen; Bristol-Myers Squibb; Gilead Sciences; Johnson & Johnson/Janssen; Lilly; Merck; Moderna Therapeutics; Pfizer; Regeneron; Vertex; West Pharmaceutical |
Consulting or Advisory Role - Pliant |
Research Funding - Abbvie (Inst); Adcentrx Therapeutics (Inst); Agenus (Inst); Alkermes (Inst); Alpine Immune Sciences (Inst); ALX Oncology (Inst); Artios (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Bolt Biotherapeutics (Inst); Boundless Bio Therapeutics (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Chugai Pharma (Inst); Compugen (Inst); Cullinan Oncology (Inst); Debiopharm Group (Inst); Deciphera (Inst); eFFECTOR Therapeutics (Inst); Elevation Oncology (Inst); Exelixis (Inst); Genmab (Inst); Gilead Sciences (Inst); GlaxoSmithKline/Tesaro (Inst); Helsinn Therapeutics (Inst); IgM Biosciences (Inst); Ikena Oncology (Inst); Incyte (Inst); InhibRx (Inst); Johnson & Johnson/Janssen (Inst); Johnson & Johnson/Janssen (Inst); Jounce Therapeutics (Inst); Kinnate Biopharma (Inst); KLUS Pharma (Inst); KSQ Therapeutics (Inst); Loxo (Inst); Macrogenics (Inst); Merck (Inst); Mersana (Inst); Mirati Therapeutics (Inst); NGM Biopharmaceuticals (Inst); Onconova Therapeutics (Inst); Palleon Pharmaceuticals (Inst); Pfizer (Inst); Pliant (Inst); PureTech (Inst); Qualigen Therapeutics (Inst); Regeneron (Inst); Repare Therapeutics (Inst); Sapience Therapeutics (Inst); Seagen (Inst); Seven and Eight Biopharmaceuticals (Inst); Shattuck Labs (Inst); SK Life Sciences (Inst); Symphogen (Inst); Syros Pharmaceuticals (Inst); Tempest Therapeutics (Inst); Theratechnologies (Inst); Tizona Therapeutics, Inc. (Inst); Treadwell Therapeutics (Inst) |
| |
|
Stock and Other Ownership Interests - Triumvira Immunologics, Inc |
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Bayer; Beigene; Daiichi Sankyo/Astra Zeneca; GlaxoSmithKline; Janssen Oncology; Jazz Pharmaceuticals; Lilly; Merck; Natera (Inst); Pfizer; Roche/Genentech; Seagen; Taiho Oncology; Takeda |
Research Funding - A*STAR (Inst); Abbvie (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); BeiGene (Inst); Curegenix (Inst); Daiichi Sankyo/Lilly (Inst); Erasca, Inc (Inst); GlaxoSmithKline (Inst); Leap Therapeutics (Inst); Lilly (Inst); Roche/Genentech (Inst); Seagen (Inst) |
Expert Testimony - Seagen |
Travel, Accommodations, Expenses - Seagen |
| |
|
Employment - Texas Oncology |
Stock and Other Ownership Interests - Next Oncology; Texas Oncology/US Oncology |
Honoraria - Syneos Health |
Consulting or Advisory Role - Revolution Medicines |
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); Ascentage Pharma (Inst); Biomea Fusion (Inst); BioNTech SE (Inst); BJ Bioscience (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Fate Therapeutics (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Immuneering (Inst); Kura Oncology (Inst); MediLink (Inst); Mirati Therapeutics (Inst); Monopteros Therapeutics (Inst); Navire (Inst); NGM Biopharmaceuticals (Inst); Nimbus Therapeutics (Inst); Pfizer (Inst); Revolution Medicines (Inst); Symphogen (Inst); Teon Therapeutics (Inst); Vividion Therapeutics (Inst); ZielBio (Inst) |
| |
|
Honoraria - Lilly Japan; Taiho Pharmaceutical; Takeda |
Consulting or Advisory Role - Abbvie; Amgen; Boehringer Ingelheim; Incyte; Janssen Oncology; Takeda |
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Carna Biosciences (Inst); Chugai Pharma (Inst); Daiichi Sankyo/UCB Japan (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Janssen Oncology (Inst); Jiangsu Hengrui Pharmaceuticals (Inst); Lilly (Inst); Merck Serono (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst) |
Travel, Accommodations, Expenses - Amgen; Chugai Pharma; Incyte |
| |
|
Employment - Rambam Health Care Campus |
Honoraria - GlaxoSmithKline |
Consulting or Advisory Role - 1E Therapeutics; GalMed Pharmacueticals; Simplivia |
Research Funding - 1E Therapeutics |
| |
|
Honoraria - AstraZeneca; Medison; Roche |
Patents, Royalties, Other Intellectual Property - provisional patent application filed |
Travel, Accommodations, Expenses - Medison |
| |
|
Honoraria - Amgen; BMS GmbH & Co. KG; Merck; Sanofi Pasteur; Servier |
Travel, Accommodations, Expenses - Pierre Fabre |
| |
|
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Nobelpharma; Ono Pharmaceutical; PAREXEL INTERNATIONAL; Pfizer; Pfizer; Pfizer; Taiho Pharmaceutical |
Consulting or Advisory Role - Rebirthel (Inst); Thyas Co. Ltd (Inst) |
Research Funding - Abbvie (Inst); Chugai Pharma (Inst); KBBM (Inst); Lilly Japan (Inst); Novartis (Inst); Otsuka (Inst); Taiho Pharmaceutical (Inst); Taisho Pharmaceutical Holdings (Inst); Takeda (Inst); Zymeworks (Inst) |
| |
|
Honoraria - Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai |
Consulting or Advisory Role - Boehringer Ingelheim; Chugai Pharma; CMIC; Eisai; Healios; Merck; Takeda |
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Carna Biosciences (Inst); Chiome Bioscience (I); Chugai Pharma (Inst); CMIC (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Genmab/Seattle Genetics (Inst); GlaxoSmithKline (Inst); InventisBio (Inst); Janssen (Inst); Kaken Pharmaceutical (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Otsuka (I); Pfizer (Inst); Rakuten Medical (Inst); Shionogi (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Toray Industries (Inst) |
| |
|
Research Funding - BeiGene |
| |
|
Consulting or Advisory Role - Amgen |
Speakers' Bureau - AstraZeneca |
| |
|
|
Research Funding - AstraZeneca/MedImmune (Inst) |
Travel, Accommodations, Expenses - Amgen; Amgen; Amgen; Roche/Genentech; Roche/Genentech |
| |
Kanwal Pratap Singh Raghav |
Honoraria - Bayer; Daiichi Sankyo/Astra Zeneca; Eisai; Merck; Seagen |
Consulting or Advisory Role - Bayer; Daiichi Sankyo/Astra Zeneca; Eisai; Merck; Seagen |
Research Funding - Abbvie (Inst); Bayer (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Eisai (Inst); Guardant Health (Inst); HiberCell (Inst); Innovent Biologics (Inst); Janssen (Inst); Merck Serono (Inst); Roche/Genentech (Inst); UCB (Inst); Xencor (Inst) |
| |
|
|
Stock and Other Ownership Interests - AbbVie |
| |
|
|
Stock and Other Ownership Interests - AbbVie |
| |
Martha Raluca Neagu Aristide |
|
Stock and Other Ownership Interests - AbbVie |
| |
|
|
Stock and Other Ownership Interests - AbbVie |
| |
Carla Biesdorf de Almeida |
|
Stock and Other Ownership Interests - AbbVie |
| |
|
No Relationships to Disclose |
| |
|
Employment - BioCytics; Carolina BioOncology Institute |
Leadership - BioCytics; Carolina BioOncology Institute |
Stock and Other Ownership Interests - BioCytics; Carolina BioOncology Institute |
Consulting or Advisory Role - Aavocyte; Abbvie; AstraZeneca/MedImmune; Boxer Capital; Genentech/Roche; Phanes Therapeutics; TERUMO; TopAlliance BioSciences Inc |
Research Funding - Abbvie; Adagene (Inst); Alkermes; Allarity Therapeutics (Inst); Apros Therapeutics; Aptevo Therapeutics (Inst); Arcus Biosciences; Ascendis Pharma (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune; Atreca (Inst); Aulos Bioscience (Inst); BioBank Online (Inst); BioNTech SE (Inst); BJ Bioscience (Inst); Bristol-Myers Squibb; Calico; Cellgene Corp. (Inst); CEM Corporation (Inst); Conjupro Biotherapeutics (Inst); Corbus Pharmaceuticals (Inst); Corvus Pharmaceuticals; CUE BioPharma (Inst); Cullinan Oncology (Inst); Curis; EMD Serono; Engineered BioPharmaceuticals (Inst); Fate Therapeutics (Inst); FLX Bio; Function Oncology (Inst); Genentech/Roche; GI Innovation (Inst); Glenmark Specialty SA (Inst); Harbour BioMed (Inst); I-Mab (Inst); IconOVir Bio (Inst); IgM Biosciences (Inst); Immune-Onc Therapeutics (Inst); Incyte; Jounce Therapeutics; Lilly/ImClone; Macrogenics; MBrace Therapeutics Inc. (Inst); Medikine (Inst); Merck (Inst); Modena TX (Inst); Molecular Templates (Inst); MT Group (Inst); Multitude Therapeutics Inc (Inst); NextCure (Inst); Nuvation Bio (Inst); PBD Biologics LTD (Inst); PEEL Therapeutics (Inst); Phanes Therapeutics (Inst); Pieris Pharmaceuticals (Inst); Pioma Chemicals (Inst); Precision for Medicine (Inst); Qurgen (Inst); Repertoire Immune Medicines (Inst); Replimune (Inst); Revolution Medicines Inc. (Inst); RiboScience (Inst); Sairopa (Inst); Seagen; Sequenom (Inst); Simcere (Inst); SK Life Sciences (Inst); STEMCELL Technologies (Inst); Tempest Therapeutics; Therapeutic BrainPower LLC (Inst); Top Alliance BioScience; Trethera (Inst); Xilio Therapeutics (Inst); Xilis (Inst); Zenshine (Inst) |
Patents, Royalties, Other Intellectual Property - BioCytics is developing intellectual property for cellular immunotherapy |